First-line Combination Treatment Based on Anlotinib

Phase 1 Unknown 80 enrolled Shanghai Chest Hospital

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients. The primary endpoints of the study are safety and objective response rate (ORR);the secondary endpoints are disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).

Timeline

Start: 2018-07-20
Primary completion: 2019-12-31
Completion: 2020-12-31

Publications

Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X, Dong Y, Teng J, Gao Z, Qiang H, Nie W, Zhao Y, Han Y, Chen Y, Han B. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC. J Thorac Oncol. 2021 Apr;16(4):643-652. doi: 10.1016/j.jtho.2020.11.026. Epub 2021 Jan 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Catequentinib	Small molecule	10 mg	—
Subject	Catequentinib	Small molecule	12 mg	—
Subject	Erlotinib	Small molecule	150 mg	—
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	500 mg/m2	Intravenous
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous

First-line Combination Treatment Based on Anlotinib

Summary

Timeline

Publications

Drugs

Indications